Investment
Report
Briefing on Financial Results for the Fiscal Year Ending March 2025: Japan
Briefing on Financial Results for the Fiscal Year This document has been prepared to provide corporate information and other details about RENOVA, Inc (“RENOVA,” hereafter) and the RENOVA Group, and does not constitute solicitation to acquire shares or other securities issued by RENOVA, whether in Japan or Information listed herein concerning industry and market trends, the economic climate and so on has been prepared based on currently available information.
RENOVA, Inc.
Report
Financial Results for the Fiscal Year Ended March 31, 2025: Mitsubishi HC Capital Inc.
Financial Results for the Fiscal Year Ended March 31, 2025 Greetings, everyone. This is Taiju Hisai, President & CEO. Thank you for taking time out of your busy schedules to attend our financial results briefing today. In addition to those gathered here at the briefing venue, we are also joined by many people watching live online. I would like to begin today’s briefing by explaining the highlights of the Financial Results for the Fiscal Year Ended March 31, 2025, which we announced yesterday.
Mitsubishi HC Capital
Report
GSK First Quarter 2025 Performance Report
Issued: Wednesday,30 April 2025, London, U.K. GSK makes strong start to 2025 with growth in sales, profits and earnings Specialty Medicines growth drives Q1 performance • Total Q1 sales £7.5 billion +2% AER; +4% CER • Specialty Medicines sales £2.9 billion (+17%); Respiratory, Immunology and Inflammation £0.8 billion (+28%); Oncology £0.4 billion (+53%); HIV sales £1.7 billion (+7%) • Vaccines sales £2.1 billion (-6%); Shingrix £0.9 billion (-7%); Meningitis vaccines £0.4 billion (+2...
GSK
